- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT03478462
Estudo de escalonamento de dose de CLR 131 em crianças, adolescentes e adultos jovens com tumores malignos recidivantes ou refratários, incluindo, entre outros, neuroblastoma, rabdomiossarcoma, sarcoma de Ewings e osteossarcoma (CLOVER-2)
Um estudo aberto, escalonamento de dose, eficácia e segurança de CLR 131 em crianças, adolescentes e adultos jovens com tumores sólidos selecionados, linfoma e tumores cerebrais malignos
The study evaluates CLR 131 in children, adolescents, and young adults with relapsed or refractory malignant solid tumors and lymphoma and recurrent or refractory malignant brain tumors for which there are no standard treatment options with curative potential.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Even with standard, highly toxic multimodality therapies and salvage regimen, most pediatric patients with primary metastatic or relapsed solid tumors are confronted with a poor prognosis. For these patients there is currently no accepted successful treatment regimen. There is a need for new drugs, including targeted radiopharmaceuticals, preferably with cancer-specific uptake and broad applicability for these rare pediatric malignancies.
CLR 131 is a radioiodinated therapeutic that exploits the selective uptake and retention of phospholipid ethers (PLEs) by malignant cells. Cellectar Biosciences' novel cancer-targeted small-molecule compound (CLR1404) is radiolabeled with the isotope iodine-131 (I-131). CLR 131 has demonstrated tumor selective uptake across numerous adult and pediatric cancer cell types. Therapeutic efficacy has been demonstrated in various pediatric and adult-type cancer xenograft models, confirming the ability of CLR 131 to target tumors.
Based on the critical unmet medical need for effective agents with novel mechanisms of action in relapsed pediatric cancers and initial preclinical and clinical experience with radioiodinated CLR1404, Cellectar Biosciences has chosen to assess CLR 131 in a phase 1 pediatric trial.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 1
Contactos e Locais
Locais de estudo
-
-
New South Wales
-
Westmead, New South Wales, Austrália, 2145
- Children's Hospital at Westmead
-
-
-
-
Ontario
-
Toronto, Ontario, Canadá, M5G1X8
- Hospital for Sick Children
-
-
-
-
California
-
Palo Alto, California, Estados Unidos, 94304
- Lucile Packard Children's Hospital
-
-
New York
-
New York, New York, Estados Unidos, 10065
- Memorial Sloan Kettering Cancer Center
-
-
North Carolina
-
Chapel Hill, North Carolina, Estados Unidos, 27708
- Duke University
-
-
Ohio
-
Cincinnati, Ohio, Estados Unidos, 45229
- Cincinnati Children's Hospital Medical Center
-
-
Texas
-
Houston, Texas, Estados Unidos, 77030
- Texas Children's Hospital
-
-
Wisconsin
-
Madison, Wisconsin, Estados Unidos, 53792
- University of Wisconsin Hospital and Clinics
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
All Patients
- Previously confirmed (histologically or cytologically) pediatric solid tumor (e.g., neuroblastoma, sarcoma), lymphoma (including Hodgkin's lymphoma), or malignant brain tumors that are clinically or radiographically suspected to be relapsed, refractory, or recurrent for which there are no standard treatment options with curative potential. Note: patients with diffuse intrinsic pontine glioma (DIPG) may enroll without histological or cytological confirmation.
- ≥ 2 years of age and ≤ 25 years of age at time of consent/assent
- If ≥ age 16 years, Karnofsky performance status of ≥ 60. If < age 16 years, Lansky performance status ≥ 60
- Platelets ≥ 75,000/µL (last transfusion, if any, must be at least 1 week prior to study registration, and, unless deemed medically necessary, no transfusions are allowed between registration and dosing)
- Absolute neutrophil count ≥ 750/µL
- Hemoglobin ≥ 8 g/dL (last transfusion must be at least 1 week prior to study registration, and, unless deemed medically necessary, no transfusions are allowed between registration and dosing)
- Using the bedside Schwartz formula, estimated GFR (creatinine clearance) > 60 ml/min/1.73m2
- Alanine aminotransferase < 3 × ULN
- Bilirubin < 2 × ULN
- Patients who have undergone autologous or allogeneic bone marrow transplant must be at least 3 months from transplant.
- Patients enrolling at total dose levels > 30 millicurie (mCi)/m2 must have availability or ability to collect an autologous hematopoietic stem cell back-up product prior to CLR 131 administration. At minimum, 2 x 10^6/kg cryopreserved CD34+ cells must be available.
- Patient or his or her legal representative is judged by the Investigator to have the initiative and means to be compliant with the protocol.
Patients with Pediatric Solid Tumor or Lymphoma
- At least 1 measurable lesion with longest diameter of at least 10 mm. Patients with a lesion(s) that are determined to be Metaiodobenzylguanidine (MIBG) or positron emission tomography (PET) positive may be enrolled at the investigator's discretion, even if not associated with a measurable lesion of at least 10 mm. Patients with neuroblastoma who have detectable disease may enroll provided they meet the requirements of the International Neuroblastoma Response Criteria.
- Patients with known brain metastases must have completed any radiotherapy or systemic treatments for brain metastases prior to enrollment; by investigator assessment be considered stable with no new signs or symptoms for at least 1 month, and on a stable dose of steroids (unchanged for three weeks prior to registration or on a steroid tapering regimen).
Patients with Recurrent or Refractory Brain Tumors
- At least 1 measurable lesion with longest diameter of at least 10 mm on any imaging sequence.
- Patients with previously known neurological deficits must be clinically stable at time of enrollment and able to complete all study related procedures. Patients with documented or newly diagnosed neurological deficits will be enrolled at the investigator's discretion.
- If patient receives steroids for neurological symptom control, the dose must be stable (unchanged for three weeks prior to registration) or on a steroid tapering regimen. Initiation of steroids per routine care immediately prior to CLR 131 dosing is acceptable.
Exclusion Criteria:
- Patients receiving active treatment for central nervous system metastases or those that are likely to require active treatment during anticipated participation in this trial. Patients with stable brain metastases treated with steroids may enroll at the investigator's discretion
- For solid tumor and lymphoma patients only, central nervous system involvement unless previously treated with surgery, systemic therapy, or radiotherapy with the patient neurologically stable. Patients with metastatic brain tumors that have been previously treated are allowed, provided the patient is neurologically stable (determined at the investigator's discretion).
- Antitumor therapy or investigational therapy, within 2 weeks of dosing. For certain types of radiation (craniospinal, total abdominal, whole lung [spot irradiation to skull-based metastases is not considered craniospinal radiation for the purposes of this study]), at least 3 months must have elapsed. No washout is required for palliative focal radiation. NOTE: Patients participating in non-interventional clinical trials (i.e., non-drug) are allowed to participate in this trial
- Patients previously treated with iodine-131 (131I)-MIBG who have already received a cumulative I-131 dose > 54 mCi/kg or who would exceed 54 mCi/kg by participating in this trial, are not eligible.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: CLR 131
CLR 131 intravenous administration |
IV dose of CLR 131, increased/decreased by dose level; single or fractionated dose
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Number of participants with dose limiting toxicities (DLT)
Prazo: up to 64 days
|
DLT will be assessed by physical examination, vital signs, and laboratory values |
up to 64 days
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Identification of recommended phase 2 dose of CLR 131 in children, adolescents, and young adults
Prazo: until non-tolerated dose is defined; dose escalation decision made upon review of data from a complete cohort (85 days after all subjects in cohort have received infusion)
|
Dose and regimen to be used in Phase 2 trials of CLR 131 in children, adolescents, and young adults |
until non-tolerated dose is defined; dose escalation decision made upon review of data from a complete cohort (85 days after all subjects in cohort have received infusion)
|
|
Determination of preliminary antitumor activity of CLR 131 in children, adolescents, and young adults
Prazo: through Day 85
|
Response assessment per applicable criteria (e.g., Neuroblastoma Response Criteria (modified); RECIST 1.1; positron emission tomography response criteria in solid tumors (PERCIST); RANO) |
through Day 85
|
|
Determination of therapeutic activity of CLR 131 in children, adolescents, and young adults
Prazo: up to 22 days post initial infusion
|
Assessment via 131-I/CLR 131 SPECT/CT scans |
up to 22 days post initial infusion
|
|
Determination of event free survival following CLR 131 infusion in children, adolescents, and young adults
Prazo: 1 month to 5 years
|
Time from first infusion of CLR 131 until progression or recurrence of disease |
1 month to 5 years
|
|
Determination of overall survival following CLR 131 infusion in children, adolescents, and young adults
Prazo: 1 month to 5 years
|
Time from first infusion of CLR 131 until death due to any reason |
1 month to 5 years
|
|
Determine dosimetry of CLR 131 in children, adolescents, and young adults
Prazo: up to 15 days post initial infusion
|
Assessment of dosimetry via whole body planar imaging |
up to 15 days post initial infusion
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Diretor de estudo: Jarrod Longcor, Cellectar Biosciences
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
- linfoma
- osteossarcoma
- Sarcoma de Ewing
- ATRT
- glioblastoma
- Linfoma Não-Hodgkin
- neuroblastoma
- meduloblastoma
- glioma de alto grau
- rabdomiossarcoma
- DIPG
- sarcoma
- Tumor de Wilms
- ependimoma
- PNET
- gliossarcoma
- câncer raro
- Linfoma de Hodgkin
- tumor desmoplásico de pequenas células redondas
- tumor maligno de células germinativas
- sarcoma sinovial
- DSRCT
- glioma pontino intrínseco difuso
- tumor rabdóide teratóide atípico
- tumor neuroectodérmico primitivo
- gliomatose cerebral
Termos MeSH relevantes adicionais
- Doenças urogenitais
- Doenças Cerebrais
- Doenças do Sistema Nervoso Central
- Doenças do Sistema Nervoso
- Neoplasias urogenitais
- Neoplasias por local
- Neoplasias
- Doenças Urogenitais Masculinas
- Doenças renais
- Doenças Urológicas
- Doenças Urogenitais Femininas
- Doenças urogenitais femininas e complicações na gravidez
- Doenças Genéticas, Congênitas
- Doenças do sistema imunológico
- Neoplasias por Tipo Histológico
- Neoplasias Glandulares e Epiteliais
- Doenças Linfáticas
- Distúrbios Linfoproliferativos
- Distúrbios imunoproliferativos
- Neoplasias Urológicas
- Astrocitoma
- Tumores Neuroectodérmicos
- Neoplasias, Células Germinativas e Embrionárias
- Neoplasias, Tecido Nervoso
- Neoplasias do Sistema Nervoso
- Neoplasias Renais
- Síndromes Neoplásicas Hereditárias
- Neoplasias de Tecidos Conjuntivos e Moles
- Tumores Neuroectodérmicos Primitivos Periféricos
- Neoplasias, Tecido Ósseo
- Neoplasias do Tecido Conjuntivo
- Neoplasias do Sistema Nervoso Central
- Neoplasias, Tecido Muscular
- Neoplasias Complexas e Mistas
- Miossarcoma
- Neoplasias Cerebrais
- Neoplasias do Tronco Encefálico
- Neoplasias Infratentoriais
- Doenças e Anormalidades Congênitas, Hereditárias e Neonatais
- Doenças hemic e linfáticas
- Glioma pontino intrínseco difuso
- Linfoma
- Glioblastoma
- Glioma
- Neuroblastoma
- Sarcoma de Ewing
- Linfoma Não-Hodgkin
- Sarcoma
- Doença de Hodgkin
- Sarcoma Sinovial
- Rabdomiossarcoma
- Gliossarcoma
- Osteossarcoma
- Ependimoma
- Meduloblastoma
- Tumores Neuroectodérmicos Primitivos
- Tumor de Wilms
- Tumor Rabdóide
- Tumor Desmoplásico de Pequenas Células Redondas
- Neoplasias Neuroepiteliais
- CLR1404
Outros números de identificação do estudo
- DCL-17-001
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .